Zydus Lifesciences share buyback opens June 4; Check entitlement ratio and details here

This is the third instance of the company carrying out a share buyback since 2022. The previous one was done back in 2024 at a price of ₹1,005 per share.

This is the third instance of the company carrying out a share buyback since 2022. The previous one was done back in 2024 at a price of ₹1,005 per share.

Latest data from the Reserve Bank of India shows a strong reserve of over $681 billion even after spending over $15 billion in the last 15 days.

A host of stocks will be in focus on June 1, including IndiGo after its quarterly loss, Glenmark Pharma on strong earnings, Lupin following a US FDA approval, and NMDC after reporting robust revenue growth. Textile stocks may also attract…

The total outflow by Foreign Portfolio Investors (FPIs) from the equity market has reached ₹2.25 lakh crore in 2026, which is higher than the ₹1.66 lakh crore pulled out during the entire 2025, according to data with the NSDL.

Investors will closely track the RBI’s monetary policy decision next week, along with developments in US-Iran negotiations, crude oil price movements and shipping activity through the Strait of Hormuz.

In his annual letter to shareholders, Adani said the conglomerate remained committed to expansion despite heightened scrutiny over the past year, adding that matters related to the group’s US legal proceedings were now ”behind us”, allowing it to focus on…

Stocks ended the week higher, boosted by gains in the technology sector and optimism over a ceasefire extension in the West Asia, and all three major market averages scored new intraday and closing records on Friday.

TTK Prestige expects induction cooktops to become a larger contributor to its business as consumer adoption accelerates, prompting the company to expand production capacity two-fold amid sustained demand momentum.

Sarda Energy & Minerals said its power operations have stabilised after planned shutdowns, with stronger seasonal power demand expected to support Q1 FY27 performance as the company advances expansion and debt reduction plans.

Poly Medicure expects its Europe business to recover and international revenue to grow 15% in FY27 as the medtech company accelerates development of advanced cardiology and orthopaedic devices to reduce import dependence and expand globally.